Skip to main content
TipRanks
Go Ultimate75% OFF

LABORATORIO REIG JOFRE (RJF) AI Stock Analysis

2 Followers
ES:RJF

LABORATORIO REIG JOFRE

(BME:RJF)

Select Model
Rating:52Neutral
Price Target:EUR 2.50â–¼(-3.85% Downside)
Action:reiterated
Date:11/07/26

The score is primarily constrained by deteriorating 2025 earnings and cash flow, despite a sound balance sheet. Weak technical momentum and a relatively high P/E with a low dividend yield provide additional downside considerations.

Positive Factors
Diversified pharmaceutical modelThe combination of proprietary pharmaceutical products and CDMO services gives RJF more than one route to revenue. Its own portfolio can support product-led growth, while outsourced development and manufacturing use existing capabilities to broaden customer and market exposure.
Negative Factors
Sharp 2025 revenue contractionThe 2025 revenue decline represents a material interruption to RJF’s earlier growth trajectory. A contraction of this scale can reduce operating leverage, weaken absorption of fixed costs, and make recovery in earnings dependent on renewed demand or improved pricing.

LABORATORIO REIG JOFRE (RJF) vs. iShares MSCI Spain ETF (EWP)

-20%-10%0%10%20%30%40%ES:RJF-2.62%EWP+22.11%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 214.07M
Dividend Yield
0.75%
Average Volume (3M)
8,493
Price to Earnings (P/E)
30.7
Beta (1Y)
0.37
Revenue Growth
-0.42%
EPS Growth
4.56%
Country
Spain
Employees
1,512
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

LABORATORIO REIG JOFRE Business Overview & Revenue Model

Company Description

Laboratorio Reig Jofre, S.A. is a pharmaceutical company dedicated to the research, development, manufacturing, and commercialization of a diverse range of medicines and nutritional supplements. Its extensive portfolio encompasses prescription drugs,...

How the Company Makes Money

RJF primarily makes money through two main revenue streams: (1) Sales of its own pharmaceutical and healthcare products, where revenue is generated by selling RJF-branded (or RJF-owned) medicines and related products to healthcare channels such as ho...

LABORATORIO REIG JOFRE Financial Statement Overview

Summary

The balance sheet is relatively strong, but the 2025 revenue and profit decline, together with sharply weaker operating and free cash flow, materially reduces the financial performance score.

Income Statement

54Neutral

Balance Sheet

72Positive

Cash Flow

38Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue332.15M331.10M338.89M316.09M271.15M236.23M
Gross Profit136.35M81.71M195.68M176.89M69.58M144.98M
EBITDA34.28M30.48M36.18M33.89M30.44M24.66M
Net Income6.89M5.02M10.38M9.41M8.11M5.09M
Balance Sheet
Total Assets420.70M396.56M344.85M330.55M321.19M324.98M
Cash, Cash Equivalents and Short-Term Investments14.78M16.84M16.08M6.36M6.88M5.16M
Total Debt119.58M98.53M58.52M53.49M61.24M67.38M
Total Liabilities197.21M170.24M130.90M126.29M126.64M136.46M
Stockholders Equity221.11M218.07M213.97M204.35M194.63M188.59M
Cash Flow
Free Cash Flow0-13.78M10.56M6.34M4.75M-5.26M
Operating Cash Flow01.51M31.34M19.11M16.15M14.50M
Investing Cash Flow0-17.82M-31.96M-12.88M-12.72M-34.70M
Financing Cash Flow016.31M5.59M-7.16M-2.04M13.67M

LABORATORIO REIG JOFRE Technical Analysis

Technical Analysis SentimentNegative
Last Price2.60

Price Trends

50DMA2.60Negative
100DMA2.64Negative
200DMA2.62Negative

Market Momentum

MACD-0.00Negative
RSI50.95Neutral
STOCH75.21Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:RJF, the sentiment is Negative. The current price of 2.60 is above the 20-day moving average (MA) of 2.58, below the 50-day MA of 2.60, and below the 200-day MA of 2.62, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 50.95 is Neutral, neither overbought nor oversold. The STOCH value of 75.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ES:RJF.

LABORATORIO REIG JOFRE Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

ES:RJF against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ES:ROVIES:ROVI76OutperformEUR 3.52B17.3129.17%1.38%14.41%69.69%
ES:GRFES:GRF75OutperformEUR 6.93B16.128.83%0.71%1.03%30.59%
ES:ALMES:ALM70OutperformEUR 2.32B31.694.81%1.73%9.67%174.00%
ES:FAEES:FAE69NeutralEUR 1.58B11.6818.19%2.52%31.88%-20.09%
ES:CBAVES:CBAV66NeutralEUR 890.17M19.5741.91%2.87%10.89%17.12%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
ES:RJFES:RJF52NeutralEUR 214.07M30.703.14%0.75%-0.42%4.56%

* General Sector Average

Performance Comparison

-20%0%20%40%ES:RJFES:ALMES:CBAVES:FAEES:GRFES:ROVIDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ES:RJF and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ES:RJFLABORATORIO REIG JOFRE2.60-0.07-2.62%
ES:ALMAlmirall SA10.64-1.64-13.33%
ES:CBAVClinica Baviera54.6014.8637.41%
ES:FAEFaes Farma5.080.5812.76%
ES:GRFGrifols (0RDU)11.611.4514.23%
ES:ROVILaboratorios Farmaceuticos Rovi69.6011.9120.65%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 07, 2026